Get the Stockscreener App
11.98
8.76%
-1.15
Pre-market:
12.00
0.02
+0.17%
Kailera Therapeutics Inc stock is traded at $11.98, with a volume of 2.76M.
It is down -8.76% in the last 24 hours and down -27.57% over the past month.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
See More
Previous Close:
$13.13
Open:
$12.85
24h Volume:
2.76M
Relative Volume:
3.24
Market Cap:
$1.55B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.28%
1M Performance:
-27.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.77
$13.12
1-Week Range:
$11.77
$13.23
52-Week Range:
$11.77
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Name
Kailera Therapeutics Inc
Sector
Industry
Phone
508-440-9475
Address
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.98 | 1.55B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-26 | Initiated | Evercore ISI | Outperform |
| May-12-26 | Initiated | JP Morgan | Overweight |
| May-12-26 | Initiated | Jefferies | Buy |
| May-12-26 | Initiated | Leerink Partners | Outperform |
| May-12-26 | Initiated | TD Cowen | Buy |
| May-12-26 | Initiated | William Blair | Outperform |
View All
Kailera Therapeutics Inc Stock (KLRA) Latest News
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
KLRA: Differentiated GLP-1 assets and strategy position the company for growth in the expanding obesity market - TradingView
Kailera at bernstein healthcare forum: betting on obesity differentiation By Investing.com - Investing.com Canada
Kailera at bernstein healthcare forum: betting on obesity differentiation - Investing.com
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5%Time to Sell? - MarketBeat
Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P Global BMI Index - marketscreener.com
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics targets obesity with GLP-1 drug, raising $718M in IPO despite 40% share drop. - Pluang
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval - Seeking Alpha
Kailera Therapeutics to Participate in Upcoming Investor Conferences - quiverquant.com
Kailera Therapeutics to Participate in September Investor Conferences - GlobeNewswire
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowTime to Sell? - MarketBeat
Four executives will appear in Kailera's September webcasts - Stock Titan
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth” - finance.yahoo.com
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - Stock Titan
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - ts2.tech
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Q2 loss widens 285% to $111.3M on R&D surge; cash runway extends to mid-2028 - scanx.trade
Kailera Therapeutics Inc Stock (KLRA) Financials Data
There is no financial data for Kailera Therapeutics Inc (KLRA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kailera Therapeutics Inc Stock (KLRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):